CA3021344A1 - Schema posologique - Google Patents
Schema posologique Download PDFInfo
- Publication number
- CA3021344A1 CA3021344A1 CA3021344A CA3021344A CA3021344A1 CA 3021344 A1 CA3021344 A1 CA 3021344A1 CA 3021344 A CA3021344 A CA 3021344A CA 3021344 A CA3021344 A CA 3021344A CA 3021344 A1 CA3021344 A1 CA 3021344A1
- Authority
- CA
- Canada
- Prior art keywords
- cysteamine
- pharmaceutically acceptable
- acceptable salt
- dose
- cystic fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3021344A CA3021344A1 (fr) | 2018-10-17 | 2018-10-17 | Schema posologique |
| AU2019360638A AU2019360638A1 (en) | 2018-10-17 | 2019-10-17 | Dosage regime |
| US17/286,282 US20210386694A1 (en) | 2018-10-17 | 2019-10-17 | Dosage regime |
| EP19786612.2A EP3866775B1 (fr) | 2018-10-17 | 2019-10-17 | Cystéamine utilisée dans le traitement des maladies pulmonaires |
| PCT/EP2019/078279 WO2020079186A1 (fr) | 2018-10-17 | 2019-10-17 | Régime posologique |
| CA3116637A CA3116637A1 (fr) | 2018-10-17 | 2019-10-17 | Regime posologique |
| ZA2021/02913A ZA202102913B (en) | 2018-10-17 | 2021-04-30 | Dosage regime |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3021344A CA3021344A1 (fr) | 2018-10-17 | 2018-10-17 | Schema posologique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3021344A1 true CA3021344A1 (fr) | 2020-04-17 |
Family
ID=70278502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3021344A Abandoned CA3021344A1 (fr) | 2018-10-17 | 2018-10-17 | Schema posologique |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA3021344A1 (fr) |
-
2018
- 2018-10-17 CA CA3021344A patent/CA3021344A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2856831T3 (es) | Una composición que comprende un antibiótico no peptídico y cisteamina | |
| TWI421097B (zh) | 用作抗微生物劑之增強劑的查耳酮 | |
| JP2015521617A5 (fr) | ||
| US9839634B2 (en) | Antibacterial agents: combination of a rifamycin and a switch region inhibitor | |
| KR20170008762A (ko) | 항균제로서의 금 (i)-포스핀 화합물 | |
| WO2012041898A1 (fr) | Combinaison de l'inhibiteur de sglt2 et d'un composé de sucre pour le traitement du diabète | |
| ES2928684T3 (es) | Agente terapéutico para la fibrosis | |
| US20200113863A1 (en) | Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases | |
| KR20170012288A (ko) | 항균제로서의 금 (i)-포스핀 화합물 | |
| EP3360547B1 (fr) | Composition pharmaceutique bactéricide comprenant l'ibuprofen | |
| WO2020117755A1 (fr) | Compositions et méthodes pour le traitement de biofilms | |
| US20160106689A1 (en) | Use | |
| EP2114406B1 (fr) | Dérivés de thioxanthène comme seuls agents antiinfectieux pour leur utilisation dans le traitement des maladies infectieuses | |
| JP2006306836A (ja) | 抗ウイルス・抗炎症作用薬剤組成物 | |
| TW201632177A (zh) | 有效對抗包括抗藥性微生物類之微生物群的組合治療 | |
| EP3866775B1 (fr) | Cystéamine utilisée dans le traitement des maladies pulmonaires | |
| CA3021344A1 (fr) | Schema posologique | |
| JP2014240401A (ja) | 感染症治療用のチオキサンテン誘導体 | |
| ES2942848T3 (es) | Derivados de tiofeno-2-amida sustituidos con difenilo y composiciones farmacéuticas de los mismos útiles como antimicrobiano | |
| SE0201837D0 (sv) | Chemical compounds | |
| JP5101521B2 (ja) | メチシリン耐性黄色ブドウ球菌をオキサシリンに対し感作する組成物および方法 | |
| ES2902456T3 (es) | Composiciones farmacéuticas que comprenden agentes antibacterianos | |
| JP6443926B2 (ja) | 新規メタロ−β−ラクタマ−ゼ阻害剤 | |
| US20230398139A1 (en) | Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections | |
| CN107847501A (zh) | 抗菌组合物以及方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20220419 |
|
| FZDE | Discontinued |
Effective date: 20220419 |